Replies to post #243969 on Biotech Values

[dewophile]

In healthcare I’ve decreased small bio positions and increased large bio and pharma that are ex US bc I think the strong dollar is a tailwind considering most generate a lot of revenue in dollars but costs are skewed towards home currency so margins are benefiting from FX (as well as reporting in home currency )
E.g. GSK